Market Overview

Goldman Sachs Upgrades Onyx Pharmaceuticals to CL-Buy


Goldman Sachs has upgraded Onyx Pharmaceuticals (NASDAQ: ONXX) from Buy to CL-Buy and has added the company to its Americas Conviction List. Price target has been raised from $45 to $47.

Posted-In: Americas Conviction Buy List Goldman SachsUpgrades Price Target Pre-Market Outlook Analyst Ratings


Related Articles (ONXX)

Get Benzinga's Newsletters